CAR-T cell therapies advance the treatment of cancer, but they are expensive and can take weeks to process. Academic ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

Robert Holt is in the Basic and Translational Research Department, BC Cancer Research Institute, Vancouver V5Z1L3, Canada, in the Department of Medical Genetics, University of British Columbia, ...

A new technique may reprogram immune cells inside the body, offering faster, simpler, and more accessible cancer treatment.

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Signaling is fundamental to how cells sense and respond to their environment—but in immune cells, those signals must be ...